2 completed, 1 recruiting, 1 unknown. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Indolent B-Cell Lymphomas: new trials by email Literature Review of Indolent B-Cell Lymphomas trials Research Report on Indolent B-Cell Lymphomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma Diffuse Large B Cell Lymphoma (DLBCL), Indolent B-Cell Lymphomas | Recruiting | Azienda USL Reggio Emilia - IRCCS | 50 | 2024-08-19 | 2026-05-05 | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies CDX-1140, CDX-301, pembrolizumab - Melanoma, Non-small Cell Lung Cancer | Phase 1 | Completed | Celldex Therapeutics | 132 | 2017-12-01 | 2024-03-28 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
| Indolent Non Follicular Lymphomas Prognostic Project Any treatment, watch and wait policy included - Indolent B-Cell Lymphomas | Completed | Fondazione Italiana Linfomi - ETS | 370 | 2011-09-01 | 2025-08-08 |
Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Hepatitis B, Chronic (1) · Hyper-IgM Immunodeficiency Syndrome (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Blood Protein Disorders (2) · Digestive System Diseases (2) · Hematologic Diseases (2) · Liver Diseases (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Adenocarcinoma (1)
Drug Therapy (1) · ibrutinib (1) · pembrolizumab (1)
Azienda USL Reggio Emilia - IRCCS (1) · Celldex Therapeutics (1) · Fondazione Italiana Linfomi - ETS (1) · The University of Hong Kong (1)
Italy (2) · Austria (1) · Brazil (1) · France (1) · Hong Kong (1) · Portugal (1) · Ukraine (1) · United States (1)
Arcaini Luca, MD (1) · Maria Elena Nizzoli, MD (1) · Yok Lam Kwong, MD(HK), (1)